<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2025-1-98-104</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1709</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Адъювантная терапия остеоартрита биорегуляционными препаратами</article-title><trans-title-group xml:lang="en"><trans-title>Adjuvant therapy of osteoarthritis with bioregulatory drugs</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4579-2836</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зоткин</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zotkin</surname><given-names>E. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евгений Германович Зоткин,</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Evgeniy Germanovich Zotkin,</p><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">ezotkin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-6126-4829</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шкиреева</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Shkireeva</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>02</month><year>2025</year></pub-date><volume>19</volume><issue>1</issue><fpage>98</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Зоткин Е.Г., Шкиреева С.Ю., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Зоткин Е.Г., Шкиреева С.Ю.</copyright-holder><copyright-holder xml:lang="en">Zotkin E.G., Shkireeva S.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1709">https://mrj.ima-press.net/mrj/article/view/1709</self-uri><abstract><p>Остеоартрит (ОА) – хроническое прогрессирующее заболевание суставов, занимающее первое место по частоте среди болезней костно-мышечной системы. ОА представляет собой серьезную общемедицинскую и социальную проблему, связанную с неуклонным ростом его распространенности. Уменьшение боли при ОА, поддержание активной повседневной деятельности и сохранение социальной функции являются основной целью лечения практически всех пациентов, страдающих этим заболеванием. Наряду с известными традиционными методами лечения ОА существуют адъювантные методы терапии. Комплексные биорегуляционные препараты – это лекарственные средства исключительно природного происхождения, состав которых подобран эмпирическим путем. Препараты этой группы обладают противовоспалительным, иммуномодулирующим и противомикробным действием, а их эффективность и безопасность доказаны в масштабных клинических исследованиях.</p></abstract><trans-abstract xml:lang="en"><p>Osteoarthritis (OA) is a chronic progressive joint disease that ranks first in the frequency of all musculoskeletal diseases. OA is a serious general medical and social problem associated with a steady increase in prevalence. Reducing the pain in OA, maintaining active daily activity and preserving social functioning are the main goals of treatment for almost all patients suffering from this disease. In addition to the well-known traditional methods of treatment of OA, there are adjuvant therapies. Complex bioregulatory drugs are drugs whose composition is put together empirically and which contain only ingredients of natural origin. Drugs of this group have anti-inflammatory, immunomodulatory and antimicrobial effects, and their efficacy and safety have been proven in large-scale clinical trials.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>биорегуляционные препараты</kwd><kwd>остеоартрит</kwd><kwd>воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bioregulatory drugs</kwd><kwd>osteoarthritis</kwd><kwd>inflammation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cui A, Li H, Wang D, et al. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020 Nov 26:29- 30:100587. doi: 10.1016/j.eclinm.2020.100587. eCollection 2020 Dec.</mixed-citation><mixed-citation xml:lang="en">Cui A, Li H, Wang D, et al. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020 Nov 26:29- 30:100587. doi: 10.1016/j.eclinm.2020.100587. eCollection 2020 Dec.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update. Arch Phys Med Rehabil. 2021 Jan;102(1):115-131. doi: 10.1016/j.apmr.2020.04.001. Epub 2020 Apr 24.</mixed-citation><mixed-citation xml:lang="en">Lo J, Chan L, Flynn S. A systematic review of the incidence, prevalence, costs, and activity and work limitations of amputation, osteoarthritis, rheumatoid arthritis, back pain, multiple sclerosis, spinal cord injury, stroke, and traumatic brain injury in the United States: a 2019 update. Arch Phys Med Rehabil. 2021 Jan;102(1):115-131. doi: 10.1016/j.apmr.2020.04.001. Epub 2020 Apr 24.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. Osteoarthritis Cartilage. 2022 Jan;30(1):10-16. doi: 10.1016/j.joca.2021.05.007. Epub 2021 May 20.</mixed-citation><mixed-citation xml:lang="en">Leifer VP, Katz JN, Losina E. The burden of OA-health services and economics. Osteoarthritis Cartilage. 2022 Jan;30(1):10-16. doi: 10.1016/j.joca.2021.05.007. Epub 2021 May 20.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Man G, Mologhianu G. Osteoarthritis pathogenesis – a complex process that involves the entire joint. J Med Life. 2014 Mar 15;7(1):37-41. Epub 2014 Mar 25.</mixed-citation><mixed-citation xml:lang="en">Man G, Mologhianu G. Osteoarthritis pathogenesis – a complex process that involves the entire joint. J Med Life. 2014 Mar 15;7(1):37-41. Epub 2014 Mar 25.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013 Apr;5(2):77-94. doi: 10.1177/1759720X12467868.</mixed-citation><mixed-citation xml:lang="en">Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013 Apr;5(2):77-94. doi: 10.1177/1759720X12467868.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Thomson A, Hilkens CMU. Synovial Macrophages in Osteoarthritis: The Key to Understanding Pathogenesis? Front Immunol. 2021 Jun 15:12:678757. doi: 10.3389/fimmu.2021.678757. eCollection 2021.</mixed-citation><mixed-citation xml:lang="en">Thomson A, Hilkens CMU. Synovial Macrophages in Osteoarthritis: The Key to Understanding Pathogenesis? Front Immunol. 2021 Jun 15:12:678757. doi: 10.3389/fimmu.2021.678757. eCollection 2021.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3(Suppl 3):S2. doi: 10.1186/ar4174. Epub 2013 Jul 24.</mixed-citation><mixed-citation xml:lang="en">Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3(Suppl 3):S2. doi: 10.1186/ar4174. Epub 2013 Jul 24.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu X, Chan YT, Yung PSH, et al. Subchondral Bone Remodeling: A Therapeutic Target for Osteoarthritis. Front Cell Dev Biol. 2021 Jan 21:8:607764. doi: 10.3389/fcell.2020.607764. eCollection 2020.</mixed-citation><mixed-citation xml:lang="en">Zhu X, Chan YT, Yung PSH, et al. Subchondral Bone Remodeling: A Therapeutic Target for Osteoarthritis. Front Cell Dev Biol. 2021 Jan 21:8:607764. doi: 10.3389/fcell.2020.607764. eCollection 2020.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fu K, Robbins SR, McDougall JJ. Osteoarthritis: the genesis of pain. Rheumatology (Oxford). 2018 May 1;57(suppl_4):iv43- iv50. doi: 10.1093/rheumatology/kex419.</mixed-citation><mixed-citation xml:lang="en">Fu K, Robbins SR, McDougall JJ. Osteoarthritis: the genesis of pain. Rheumatology (Oxford). 2018 May 1;57(suppl_4):iv43- iv50. doi: 10.1093/rheumatology/kex419.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">O’Neill TW, Parkes MJM, Maricar N, et al. Synovial tissue volume: a treatment target in knee osteoarthritis (OA). Ann Rheum Dis. 2016 Jan;75(1):84-90. doi: 10.1136/annrheumdis-2014-206927. Epub 2015 Jun 26.</mixed-citation><mixed-citation xml:lang="en">O’Neill TW, Parkes MJM, Maricar N, et al. Synovial tissue volume: a treatment target in knee osteoarthritis (OA). Ann Rheum Dis. 2016 Jan;75(1):84-90. doi: 10.1136/annrheumdis-2014-206927. Epub 2015 Jun 26.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Batushansky A, Zhu S, Komaravolu RK, et al. Fundamentals of OA. an initiative of osteoarthritis and cartilage. Obesity and metabolic factors in OA. Osteoarthritis Cartilage. 2022 Apr;30(4):501-515. doi: 10.1016/j.joca.2021.06.013. Epub 2021 Sep 17.</mixed-citation><mixed-citation xml:lang="en">Batushansky A, Zhu S, Komaravolu RK, et al. Fundamentals of OA. an initiative of osteoarthritis and cartilage. Obesity and metabolic factors in OA. Osteoarthritis Cartilage. 2022 Apr;30(4):501-515. doi: 10.1016/j.joca.2021.06.013. Epub 2021 Sep 17.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mobasheri A, Rayman MP, Gualillo O, et al. The role of metabolism in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2017 May;13(5):302-311. doi: 10.1038/nrrheum.2017.50. Epub 2017 Apr 6.</mixed-citation><mixed-citation xml:lang="en">Mobasheri A, Rayman MP, Gualillo O, et al. The role of metabolism in the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2017 May;13(5):302-311. doi: 10.1038/nrrheum.2017.50. Epub 2017 Apr 6.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Long H, Cao R, Yin H, et al. Associations between obesity, diabetes mellitus, and cardiovascular disease with progression states of knee osteoarthritis (KOA). Aging Clin Exp Res. 2023 Feb;35(2):333-340. doi: 10.1007/s40520-022-02312-8. Epub 2022 Dec 16.</mixed-citation><mixed-citation xml:lang="en">Long H, Cao R, Yin H, et al. Associations between obesity, diabetes mellitus, and cardiovascular disease with progression states of knee osteoarthritis (KOA). Aging Clin Exp Res. 2023 Feb;35(2):333-340. doi: 10.1007/s40520-022-02312-8. Epub 2022 Dec 16.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Berenbaum F, Griffin TM, Liu-Bryan R. Review: metabolic regulation of inflammation in osteoarthritis. Arthritis Rheumatol. 2017 Jan;69(1):9-21. doi: 10.1002/art.39842.</mixed-citation><mixed-citation xml:lang="en">Berenbaum F, Griffin TM, Liu-Bryan R. Review: metabolic regulation of inflammation in osteoarthritis. Arthritis Rheumatol. 2017 Jan;69(1):9-21. doi: 10.1002/art.39842.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Dell’Isola A, Pihl K, Turkiewicz A, et al. Risk of comorbidities following physician-diagnosed knee or hip osteoarthritis: a registerbased cohort study. Arthritis Care Res (Hoboken). 2022 Oct;74(10):1689-1695. doi: 10.1002/acr.24717. Epub 2022 Jun 22.</mixed-citation><mixed-citation xml:lang="en">Dell’Isola A, Pihl K, Turkiewicz A, et al. Risk of comorbidities following physician-diagnosed knee or hip osteoarthritis: a registerbased cohort study. Arthritis Care Res (Hoboken). 2022 Oct;74(10):1689-1695. doi: 10.1002/acr.24717. Epub 2022 Jun 22.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fonseca-Rodrigues D, Rodrigues A, Martins T, et al. Correlation between pain severity and levels of anxiety and depression in osteoarthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Dec 24;61(1):53-75. doi: 10.1093/rheumatology/keab512.</mixed-citation><mixed-citation xml:lang="en">Fonseca-Rodrigues D, Rodrigues A, Martins T, et al. Correlation between pain severity and levels of anxiety and depression in osteoarthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Dec 24;61(1):53-75. doi: 10.1093/rheumatology/keab512.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Veronese N, Honvo G, Bruyere O, et al. Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clin Exp Res. 2023 Feb;35(2):245-252. doi: 10.1007/s40520-022-02289-4. Epub 2022 Nov 4.</mixed-citation><mixed-citation xml:lang="en">Veronese N, Honvo G, Bruyere O, et al. Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clin Exp Res. 2023 Feb;35(2):245-252. doi: 10.1007/s40520-022-02289-4. Epub 2022 Nov 4.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Veronese N, Stubbs B, Solmi M, et al. Osteoarthristis increases the risk of cardiovascular disease: data from the osteoarthritis initiative. J Nutr Health Aging. 2018;22(3): 371-376. doi: 10.1007/s12603-017-0941-0.</mixed-citation><mixed-citation xml:lang="en">Veronese N, Stubbs B, Solmi M, et al. Osteoarthristis increases the risk of cardiovascular disease: data from the osteoarthritis initiative. J Nutr Health Aging. 2018;22(3): 371-376. doi: 10.1007/s12603-017-0941-0.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Perruccio AV, Zahid S, Yip C, et al. Cardiovascular Risk Profile and Osteoarthritis-Considering Sex and Multisite Joint Involvement: A Canadian Longitudinal Study on Aging. Arthritis Care Res (Hoboken). 2023 Apr;75(4):893-901. doi: 10.1002/acr.24826. Epub 2022 Nov 20.</mixed-citation><mixed-citation xml:lang="en">Perruccio AV, Zahid S, Yip C, et al. Cardiovascular Risk Profile and Osteoarthritis-Considering Sex and Multisite Joint Involvement: A Canadian Longitudinal Study on Aging. Arthritis Care Res (Hoboken). 2023 Apr;75(4):893-901. doi: 10.1002/acr.24826. Epub 2022 Nov 20.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Neogi T, Felson D, Niu J, et al. Association between radiographic features of knee osteoarthritis and pain: Results from two cohort studies. BMJ. 2009 Aug 21:339:b2844. doi: 10.1136/bmj.b2844.</mixed-citation><mixed-citation xml:lang="en">Neogi T, Felson D, Niu J, et al. Association between radiographic features of knee osteoarthritis and pain: Results from two cohort studies. BMJ. 2009 Aug 21:339:b2844. doi: 10.1136/bmj.b2844.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bacon K, Lavalley MP, Jafarzadeh SR, Felson D. Does cartilage loss cause pain in osteoarthritis and if so, how much? Ann Rheum Dis. 2020 Aug;79(8):1105-1110. doi: 10.1136/annrheumdis-2020-217363. Epub 2020 May 7.</mixed-citation><mixed-citation xml:lang="en">Bacon K, Lavalley MP, Jafarzadeh SR, Felson D. Does cartilage loss cause pain in osteoarthritis and if so, how much? Ann Rheum Dis. 2020 Aug;79(8):1105-1110. doi: 10.1136/annrheumdis-2020-217363. Epub 2020 May 7.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wang K, Kim HA, Felson DT, et al. Radiographic Knee Osteoarthritis and Knee Pain: Cross-sectional study from Five Different Racial/Ethnic Populations. Sci Rep. 2018 Jan 22;8(1):1364. doi: 10.1038/s41598-018-19470-3.</mixed-citation><mixed-citation xml:lang="en">Wang K, Kim HA, Felson DT, et al. Radiographic Knee Osteoarthritis and Knee Pain: Cross-sectional study from Five Different Racial/Ethnic Populations. Sci Rep. 2018 Jan 22;8(1):1364. doi: 10.1038/s41598-018-19470-3.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Malfait AM, Miller RE, Miller RJ. Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives. Rheum Dis Clin North Am. 2021 May;47(2): 165-180. doi: 10.1016/j.rdc.2020.12.002.</mixed-citation><mixed-citation xml:lang="en">Malfait AM, Miller RE, Miller RJ. Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives. Rheum Dis Clin North Am. 2021 May;47(2): 165-180. doi: 10.1016/j.rdc.2020.12.002.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Clauw DJ, Hassett AL. The role of centralised pain in osteoarthritis. Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5): 79-84. Epub 2017 Sep 29.</mixed-citation><mixed-citation xml:lang="en">Clauw DJ, Hassett AL. The role of centralised pain in osteoarthritis. Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5): 79-84. Epub 2017 Sep 29.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Miller RJ, Malfait A-M, Miller RE. The innate immune response as a mediator of osteoarthritis pain. Osteoarthritis Cartilage. 2020 May;28(5):562-571. doi: 10.1016/j.joca.2019.11.006. Epub 2019 Dec 17.</mixed-citation><mixed-citation xml:lang="en">Miller RJ, Malfait A-M, Miller RE. The innate immune response as a mediator of osteoarthritis pain. Osteoarthritis Cartilage. 2020 May;28(5):562-571. doi: 10.1016/j.joca.2019.11.006. Epub 2019 Dec 17.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Cedraschi C, Delezay S, Marty M, et al. “Let’s talk about OA pain”: A qualitative analysis of the perceptions of people suffering from OA. Towards the development of a specific pain OA-related questionnaire, the Osteoarthritis Symptom Inventory Scale (OASIS). PLoS One. 2013 Nov 11;8(11): e79988. doi: 10.1371/journal.pone.0079988. eCollection 2013.</mixed-citation><mixed-citation xml:lang="en">Cedraschi C, Delezay S, Marty M, et al. “Let’s talk about OA pain”: A qualitative analysis of the perceptions of people suffering from OA. Towards the development of a specific pain OA-related questionnaire, the Osteoarthritis Symptom Inventory Scale (OASIS). PLoS One. 2013 Nov 11;8(11): e79988. doi: 10.1371/journal.pone.0079988. eCollection 2013.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Griffin TM, Scanzello CR. Innate inflammation and synovial macrophages in osteoarthritis pathophysiology. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):57-63. Epub 2019 Oct 15.</mixed-citation><mixed-citation xml:lang="en">Griffin TM, Scanzello CR. Innate inflammation and synovial macrophages in osteoarthritis pathophysiology. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):57-63. Epub 2019 Oct 15.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Deyle GD, Allen CS, Allison SC, et al. Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee. N Engl J Med. 2020 Apr 9;382(15):1420-1429. doi: 10.1056/NEJMoa1905877.</mixed-citation><mixed-citation xml:lang="en">Deyle GD, Allen CS, Allison SC, et al. Physical Therapy versus Glucocorticoid Injection for Osteoarthritis of the Knee. N Engl J Med. 2020 Apr 9;382(15):1420-1429. doi: 10.1056/NEJMoa1905877.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017 May 16; 317(19):1967-1975. doi: 10.1001/jama.2017.5283.</mixed-citation><mixed-citation xml:lang="en">McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017 May 16; 317(19):1967-1975. doi: 10.1001/jama.2017.5283.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Buckley CD, Gilroy DW, Serhan CN, et al. The resolution of inflammation. Nat Rev Immunol. 2013 Jan;13(1):59-66. doi: 10.1038/nri3362. Epub 2012 Nov 30.</mixed-citation><mixed-citation xml:lang="en">Buckley CD, Gilroy DW, Serhan CN, et al. The resolution of inflammation. Nat Rev Immunol. 2013 Jan;13(1):59-66. doi: 10.1038/nri3362. Epub 2012 Nov 30.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013 Jul;19(7):822-4. doi: 10.1038/nm.3260.</mixed-citation><mixed-citation xml:lang="en">Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013 Jul;19(7):822-4. doi: 10.1038/nm.3260.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017 Jun 10;389(10086): 2328-2337. doi: 10.1016/S0140-6736 (17)31472-1.</mixed-citation><mixed-citation xml:lang="en">McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017 Jun 10;389(10086): 2328-2337. doi: 10.1016/S0140-6736 (17)31472-1.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013 Aug 22; 369(8):754-62. doi: 10.1056/NEJMct1209614.</mixed-citation><mixed-citation xml:lang="en">Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013 Aug 22; 369(8):754-62. doi: 10.1056/NEJMct1209614.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Lämmermann T, Afonso PV, Angermann BR, et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature. 2013 Jun 20;498(7454):371-5. doi: 10.1038/nature12175. Epub 2013 May 26.</mixed-citation><mixed-citation xml:lang="en">Lämmermann T, Afonso PV, Angermann BR, et al. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature. 2013 Jun 20;498(7454):371-5. doi: 10.1038/nature12175. Epub 2013 May 26.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001 Jul;2(7):612-9. doi: 10.1038/89759.</mixed-citation><mixed-citation xml:lang="en">Levy BD, Clish CB, Schmidt B, et al. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001 Jul;2(7):612-9. doi: 10.1038/89759.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Sogawa Y, Ohyama T, Maeda H, Hirahara K. Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo. Immunology. 2011 Mar;132(3): 441-50. doi: 10.1111/j.1365-2567.2010.03367.x. Epub 2010 Oct 29.</mixed-citation><mixed-citation xml:lang="en">Sogawa Y, Ohyama T, Maeda H, Hirahara K. Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo. Immunology. 2011 Mar;132(3): 441-50. doi: 10.1111/j.1365-2567.2010.03367.x. Epub 2010 Oct 29.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Uderhardt S, Herrmann M, Oskolkova OV, et al. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity. 2012 May 25;36(5):834-46. doi: 10.1016/j.immuni.2012.03.010. Epub 2012 Apr 12.</mixed-citation><mixed-citation xml:lang="en">Uderhardt S, Herrmann M, Oskolkova OV, et al. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity. 2012 May 25;36(5):834-46. doi: 10.1016/j.immuni.2012.03.010. Epub 2012 Apr 12.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Uderhardt S, Ackermann JA, Fillep T, et al. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J Exp Med. 2017 Jul 3; 214(7):2121-2138. doi: 10.1084/jem.20161070. Epub 2017 May 31.</mixed-citation><mixed-citation xml:lang="en">Uderhardt S, Ackermann JA, Fillep T, et al. Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. J Exp Med. 2017 Jul 3; 214(7):2121-2138. doi: 10.1084/jem.20161070. Epub 2017 May 31.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">McGrath EE, Marriott HM, Lawrie A, et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol. 2011 Nov;90(5): 855-65. doi: 10.1189/jlb.0211062. Epub 2011 May 11.</mixed-citation><mixed-citation xml:lang="en">McGrath EE, Marriott HM, Lawrie A, et al. TNF-related apoptosis-inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc Biol. 2011 Nov;90(5): 855-65. doi: 10.1189/jlb.0211062. Epub 2011 May 11.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol. 1999 Jan 1;162(1):480-5.</mixed-citation><mixed-citation xml:lang="en">Brown SB, Savill J. Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol. 1999 Jan 1;162(1):480-5.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gagliani N, Amezcua Vesely MC, Iseppon A, et al. TH17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015 Jul 9;523(7559):221-5. doi: 10.1038/nature14452. Epub 2015 Apr 29.</mixed-citation><mixed-citation xml:lang="en">Gagliani N, Amezcua Vesely MC, Iseppon A, et al. TH17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015 Jul 9;523(7559):221-5. doi: 10.1038/nature14452. Epub 2015 Apr 29.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Li MO, Sarkisian MR, Mehal WZ, et al. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science. 2003 Nov 28;302(5650):1560-3. doi: 10.1126/science.1087621.</mixed-citation><mixed-citation xml:lang="en">Li MO, Sarkisian MR, Mehal WZ, et al. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science. 2003 Nov 28;302(5650):1560-3. doi: 10.1126/science.1087621.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi N. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. 2007 Dec; 27(6):927-40. doi: 10.1016/j.immuni.2007.11.011.</mixed-citation><mixed-citation xml:lang="en">Kobayashi N. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity. 2007 Dec; 27(6):927-40. doi: 10.1016/j.immuni.2007.11.011.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. 2002 Jan;109(1):41-50. doi: 10.1172/JCI11638.</mixed-citation><mixed-citation xml:lang="en">Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. 2002 Jan;109(1):41-50. doi: 10.1172/JCI11638.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013 Apr 25; 496(7446):445-55. doi: 10.1038/nature12034.</mixed-citation><mixed-citation xml:lang="en">Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature. 2013 Apr 25; 496(7446):445-55. doi: 10.1038/nature12034.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Ma WT, Gao F, Gu K, Chen DK. The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review. Front Immunol. 2019 May 24:10:1140. doi: 10.3389/fimmu.2019.01140. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Ma WT, Gao F, Gu K, Chen DK. The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review. Front Immunol. 2019 May 24:10:1140. doi: 10.3389/fimmu.2019.01140. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Sica A, Erreni M, Allavena P, Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015 Nov;72(21):4111-26. doi: 10.1007/s00018-015-1995-y. Epub 2015 Jul 26.</mixed-citation><mixed-citation xml:lang="en">Sica A, Erreni M, Allavena P, Porta C. Macrophage polarization in pathology. Cell Mol Life Sci. 2015 Nov;72(21):4111-26. doi: 10.1007/s00018-015-1995-y. Epub 2015 Jul 26.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Csуka B, Selmeczy Z, Koscsу B, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 2012 Jan;26(1):376-86. doi: 10.1096/fj.11-190934. Epub 2011 Sep 16.</mixed-citation><mixed-citation xml:lang="en">Csуka B, Selmeczy Z, Koscsу B, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 2012 Jan;26(1):376-86. doi: 10.1096/fj.11-190934. Epub 2011 Sep 16.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Mao X, Xing H, Mao A, et al. Netrin-1 attenuates cardiac ischemia reperfusion injury and generates alternatively activated macrophages. Inflammation. 2014 Apr;37(2):573-80. doi: 10.1007/s10753-013-9771-3.</mixed-citation><mixed-citation xml:lang="en">Mao X, Xing H, Mao A, et al. Netrin-1 attenuates cardiac ischemia reperfusion injury and generates alternatively activated macrophages. Inflammation. 2014 Apr;37(2):573-80. doi: 10.1007/s10753-013-9771-3.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Gerlach BD, Ampomah PB, Yurdagul A Jr, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 2021 Dec 7;33(12): 2445-2463.e8. doi: 10.1016/j.cmet.2021. 10.015. Epub 2021 Nov 15.</mixed-citation><mixed-citation xml:lang="en">Gerlach BD, Ampomah PB, Yurdagul A Jr, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 2021 Dec 7;33(12): 2445-2463.e8. doi: 10.1016/j.cmet.2021. 10.015. Epub 2021 Nov 15.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Perretti M, Leroy X, Bland EJ, MonteroMelendez T. Resolution pharmacology: Opportunities for therapeutic innovation in inflammation. Trends Pharmacol Sci. 2015 Nov; 36(11):737-755. doi: 10.1016/j.tips.2015.07.007. Epub 2015 Nov 2.</mixed-citation><mixed-citation xml:lang="en">Perretti M, Leroy X, Bland EJ, MonteroMelendez T. Resolution pharmacology: Opportunities for therapeutic innovation in inflammation. Trends Pharmacol Sci. 2015 Nov; 36(11):737-755. doi: 10.1016/j.tips.2015.07.007. Epub 2015 Nov 2.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Barnig C, Frossard N, Levy BD. Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther. 2018 Jun:186:98-113. doi: 10.1016/j.pharmthera.2018.01.004. Epub 2018 Jan 20.</mixed-citation><mixed-citation xml:lang="en">Barnig C, Frossard N, Levy BD. Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther. 2018 Jun:186:98-113. doi: 10.1016/j.pharmthera.2018.01.004. Epub 2018 Jan 20.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016 Aug;15(8):551-67. doi: 10.1038/nrd.2016.39. Epub 2016 Mar 29.</mixed-citation><mixed-citation xml:lang="en">Fullerton JN, Gilroy DW. Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 2016 Aug;15(8):551-67. doi: 10.1038/nrd.2016.39. Epub 2016 Mar 29.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun 5;510(7503):92-101. doi: 10.1038/nature13479.</mixed-citation><mixed-citation xml:lang="en">Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014 Jun 5;510(7503):92-101. doi: 10.1038/nature13479.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Julliard WA, Myo YPA, Perelas A, et al. Specialized pro-resolving mediators as modulators of immune responses. Semin Immunol. 2022 Jan:59:101605. doi: 10.1016/j.smim.2022.101605. Epub 2022 Jun 2.</mixed-citation><mixed-citation xml:lang="en">Julliard WA, Myo YPA, Perelas A, et al. Specialized pro-resolving mediators as modulators of immune responses. Semin Immunol. 2022 Jan:59:101605. doi: 10.1016/j.smim.2022.101605. Epub 2022 Jun 2.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Kourtzelis I, Li X, Mitroulis I, et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. Nat Immunol. 2019 Jan;20(1):40-49. doi: 10.1038/s41590-018-0249-1. Epub 2018 Nov 19.</mixed-citation><mixed-citation xml:lang="en">Kourtzelis I, Li X, Mitroulis I, et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. Nat Immunol. 2019 Jan;20(1):40-49. doi: 10.1038/s41590-018-0249-1. Epub 2018 Nov 19.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Лила АМ, Мазуров ВИ, Мартынов АИ, и др. Резолюция консенсуса экспертов Российской Федерации по диагностике и лечению остеоартрита 2022. Современная ревматология. 2022;16(6):106-116. doi: 10.14412/1996-7012-2022-6-106-116</mixed-citation><mixed-citation xml:lang="en">Lila AM, Mazurov VI, Martynov AI, et al. Resolution of the consensus of the Russian Federation experts on the diagnosis and treatment of osteoarthritis, 2022. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022;16(6):106-116. (In Russ.). doi: 10.14412/1996-7012-2022-6-106-116</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЛИ, Мазуров ВИ, Зонова ЕВ и др. Результаты клинического исследования препаратов Траумель® С и Цель® Т у пациентов с остеоартритом коленного сустава, имеющих сопутствующие сердечнососудистые заболевания. Современная ревматология. 2023;17(5):79-86. doi: 10.14412/1996-7012-2023-5-79-86</mixed-citation><mixed-citation xml:lang="en">Alekseeva LI, Mazurov VI, Zonova EV, et al. Results of a clinical study of Traumeel® S and Zeel® T in patients with knee osteoarthritis and concomitant cardiovascular disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2023;17(5):79-86. (In Russ.). doi: 10.14412/1996-7012-2023-5-79-86</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">St Laurent G, Seilheimer B, Tackett M, et al. Deep Sequencing Transcriptome Analysis of Murine Wound Healing: Effects of a Multicomponent, Multitarget Natural Product Therapy-Tr14. Front Mol Biosci. 2017 Aug 17;4:57. doi: 10.3389/fmolb.2017.00057. eCollection 2017.</mixed-citation><mixed-citation xml:lang="en">St Laurent G, Seilheimer B, Tackett M, et al. Deep Sequencing Transcriptome Analysis of Murine Wound Healing: Effects of a Multicomponent, Multitarget Natural Product Therapy-Tr14. Front Mol Biosci. 2017 Aug 17;4:57. doi: 10.3389/fmolb.2017.00057. eCollection 2017.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Jordan PM, van Goethem E, Müller AM, et al. The Natural Combination Medicine Traumeel (Tr14) Improves Resolution of Inflammation by Promoting the Biosynthesis of Specialized Pro-Resolving Mediators. Pharmaceuticals (Basel). 2021 Nov 3;14(11):1123. doi: 10.3390/ph14111123.</mixed-citation><mixed-citation xml:lang="en">Jordan PM, van Goethem E, Müller AM, et al. The Natural Combination Medicine Traumeel (Tr14) Improves Resolution of Inflammation by Promoting the Biosynthesis of Specialized Pro-Resolving Mediators. Pharmaceuticals (Basel). 2021 Nov 3;14(11):1123. doi: 10.3390/ph14111123.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
